Overactive bladder, nocturia, bladder pain and other bothersome lower urinary tract symptoms
Expert-Guided Poster Tour 09

**Sunday 17 March**
**13:15 - 15:15**

**Location:** Green Area, Room B

**Chairs:** F.C. Burkhard, Bern (CH)
A.G. Giannantoni, Perugia (IT)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

13:45 - 13:48

**Introduction**
F.C. Burkhard, Bern (CH)
A.G. Giannantoni, Perugia (IT)

**PT220**

Longitudinal intravital imaging of transplanted mesenchymal stem cells elucidates their functional integration and therapeutic potency in an animal model of interstitial cystitis/bladder pain syndrome

By: Ryu C-M.¹, Shin J.H.¹, Yu H.Y.¹, Lee J.¹, Shin D-M.², Choo M-S.¹
¹Asan Medical Center, Dept. of Urology, Seoul, South Korea, ²Asan Medical Center, Dept. of Biomedical Sciences, Seoul, South Korea

**PT221**

Bladder pain induced by chronic stress is mediated by a systemic increase of nerve growth factor involving the activation of adrenoceptors

By: Dias B.¹, Cruz F.¹, Charrua A.²
¹Faculty of Medicine of University of Porto, Dept. of Urology, Porto, Portugal, ²Faculty of Medicine of University of Porto, Dept. of Biomedicine, Porto, Portugal

**PT222**

Anti-inflammatory mechanism of indoleamine 2,3-dioxygenase inhibition in the chronic prostatic inflammation

By: Ohira S.¹, Nishishita N.², Tone S.³, Hara R.¹, Fujii T.¹, Miyaji Y.¹, Nagai A.¹
¹Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan, ²Graduate School of Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan, ³Graduate School of Tokyo Denki University, Dept. of Life Science and Engineering, Hiki-gun, Saitama, Japan

**PT223**

The role of GM-CSF in a mouse model of experimental autoimmune prostatitis
PT224

Palmitoylethanolamide/polydatin as add-on therapy in pain resistant patients with interstitial cystitis/bladder painful syndrome

By: Gubbiotti M. 1, Illiano E. 2, Costantini E. 2, Giannantoni A. 3
1Istituto Serafico di Assisi, University of Perugia, Dept. of Biomedical and Surgical Sciences, Perugia, Italy, 2University of Perugia, Dept. of Biomedical and Surgical Sciences, Andrological and Urogynaecological Clinic, Perugia, Italy, 3University of Siena, Dept. of Medical and Surgical Sciences and Neurosciences, Siena, Italy

PT225

Intravesical therapy for interstitial cystitis/bladder pain syndrome: A systematic review and network meta-analysis

By: Yeh T-C. 1, Chen P-C. 2, Chang H-C. 3, Tu Y-K. 4
1National Taiwan University Hospital Hsin-Chu Branch, Dept. of Urology, Hsinchu City, Taiwan, 2En Chu Kong Hospital, Dept. of Urology, New Taipei City, Taiwan, 3National Taiwan University Hospital, Dept. of Urology, Taipei City, Taiwan, 4National Taiwan University, Institute of Epidemiology and Preventive Medicine, Taipei City, Taiwan

PT226

Factors affecting the period between the first and second hydrodistension in females with painful bladder syndrome and interstitial cystitis

1Pusan National University Hospital, Dept. of Urology, Busan, South Korea, 2BHS Hanseo Hospital, Dept. of Urology, Busan, South Korea, 3Kosin University College of Medicine, Dept. of Urology, Busan, South Korea, 4Dong-A University Hospital, Dept. of Urology, Busan, South Korea, 5Inje University Busan Paik Hospital, Dept. of Urology, Busan, South Korea, 6Samsung Changwon Hospital, Dept. of Urology, Busan, South Korea, 7Ulsan-Jeil Hospital, Dept. of Urology, Ulsan, South Korea, 8Pusan National University Yangsan Hospital, Dept. of Urology, Yangsan, South Korea

PT227

Botulin toxin type A injections during chronic pelvic pain syndrome

By: Khelaia A.
National Center of Urology, Dept. of Urology, Tbilisi, Georgia

PT228

Long-term follow-up after cystectomy for bladder pain syndrome: Pain status, sexual function and quality of life

By: Mateu Arrom L. 1, Gutierrez Ruiz C. 1, Mayordomo O. 1, Martínez V. 1, Palou J. 2, Errando C. 1
1Fundació Puigvert, Dept. of Functional Urology and Urodynamics, Barcelona, Spain, 2Fundació Puigvert, Dept. of Urology, Barcelona, Spain

PT229

Therapeutic effect of tadalafil in the chronic prostatitis
| PT230 | **Assessment of AV002 by age and gender for the treatment of patients with nocturia: A pooled analysis of two phase 3 trials** |
| PT231 | **Improvement in first uninterrupted sleep period and quality of life after treatment with AV002, an emulsified microdose desmopressin nasal spray, in patients with overactive bladder and nocturnal polyuria** |
| PT232 | **Effect of salt reduction on nocturia persistent after administration of mirabegron for overactive bladder** |
| PT233 | **Efficacy of the novel β3 adrenergic receptor agonist vibegron for the treatment of nocturia in patients with overactive bladder: A post hoc analysis of phase 3 study** |
| PT234 | **Salt intake reduction as a treatment option for overactive bladder** |
| PT235 | **Exploration of litoxetine (LTX): A potential novel treatment for mixed urinary incontinence (MUI)** |
PT236
Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in Caucasian patients with overactive bladder

By: Kasyan G.R., Kolontarev K.B., Pushkar D.Y.
Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia

PT237
Chance of OAB patients to become symptom-free upon anti-muscarinic treatment depends on age and gender

By: Michel M.C.1, Murgas S.2, Oelke M.3, Schneider T.4
1Johannes Gutenberg University, Dept. of Pharmacology, Mainz, Germany, 2Apogepha Arzneimittel GmbH, Dept. of Medicine, Dresden, Germany, 3St. Antonius Hospital, Dept. of Urology, Gronau, Germany, 4Praxis-Klinik Rhein-Ruhr, Dept. of Urology, Mülheim, Germany

PT238
Combination of alpha blocker and phosphodiesterase 5 inhibitors versus alpha blocker monotherapy for lower urinary tract symptoms associated with benign prostate hyperplasia: A systematic review and meta-analysis

By: Chen P-C.1, Yeh T-C.2
1En Chu Kong Hospital, Dept. of Urology, New Taipei City, Taiwan, 2National Taiwan University Hospital Hsin-Chu Branch, Dept. of Urology, Hsin-Chu, Taiwan

PT239
Is the combination of alpha-blocker and phosphodiesterase-5 inhibitor better in improving the lower urinary tract symptoms and erectile dysfunction in comparison to monotherapy? A systematic review and meta-analysis

By: Adamou C.1, Kallidonis P.1, Kotsiris D.1, Ntasiotis P.1, Verze P.2, Athanasopoulos A.1
1University hospital of Patras, Dept. of Urology, Patra, Greece, 2University of Naples, Dept. of Urology, Naples, Italy

PT240
Benefit-risk evaluation of approved pharmacotherapies for the treatment of overactive bladder: A sensitivity analysis of benefits versus safety for individual OAB symptoms using multi-criteria decision analysis modelling

1University of Sheffield, Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, 2London School of Economics, Dept. of Management, London, United Kingdom, 3Universidad de la Laguna, Dept. of Urology, Santa Cruz de Tenerife, Spain, 4Sorbonne Université, Dept. of Urology, Paris, France, 5Leuven University, Dept. of Development and Regeneration, Leuven, Belgium, 6Medical University of Vienna, Dept. of Obstetrics and Gynaecology, Vienna, Italy, 7Gothenburg University, Dept. of Obstetrics and Gynaecology, Gothenburg, Sweden, 8Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, 9Sapienza University, Dept. of Urology, Rome, Italy, 10University of Alberta, Dept. of Medicine, Alberta, Canada
PT241

Multi-criteria decision analysis modelling to help physicians optimise treatment in patients diagnosed with overactive bladder

By: Miron ska E.1, Phillips L.2, Castro-Diaz D.3, Chartier-Kastler E.4, De Ridder D.5, Kölbl H.6, Milsom I.7, Pushkar D.8, Tubaro A.9, Wagg A.10, Chapple C.1

1University of Sheffield, Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, 2London School of Economics, Dept. of Management, London, United Kingdom, 3Universidad de la Laguna, Dept. of Urology, Santa Cruz de Tenerife, Spain, 4Sorbonne Université, Dept. of Urology, Paris, France, 5Leuven University, Dept. of Development and Regeneration, Leuven, Belgium, 6Medical University of Vienna, Dept. of Obstetrics and Gynaecology, Vienna, Italy, 7Gothenburg University, Dept. of Obstetrics and Gynaecology, Gothenburg, Sweden, 8Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, 9Sapienza University, Dept. of Urology, Rome, Italy, 10University of Alberta, Dept. of Medicine, Alberta, Canada

PT242

Urinary function improves in hypogonadal men receiving long-term treatment with testosterone compared to a hypogonadal control group: 6471 Patient-years of clinical experience

By: Haider K.S.1, Haider A.1, Doros G.2, Traish A.3

1Praxis Dr. Haider, Dept. of Urology, Bremerhaven, Germany, 2Boston University School of Public Health, Dept. of Epidemiology and Statistics, Boston, United States of America, 3Boston University School of Medicine, Dept. of Biochemistry and Dept. of Urology, Boston, United States of America

PT243

Different types of catheters for intermittent self-catheterization: A systematic review and network meta-analysis

By: Ye D., Chen Y.T., Jian Z.Y., Li H., Wang K.J.

West China Hospital, Sichuan University, Dept. of Urology, Laboratory of Reconstructive Urology, Chengdu, China

PT244

Patients with severe benign prostatic hyperplasia have lower levels of plasmatic serotonin

By: Oliveira Da Mota P.1, Fernandes C.1, De Sousa Morais N.A.1, Moura R.2, Lima E.1, Correia-Pinto J.1, Dias E.1

1University of Minho, School of Medicine, Braga, Portugal, 2University of Minho, Life and Health Sciences Research Institute, Braga, Portugal

PT245

PTNS: Still going strong or an ever ending story?

By: Te Dorsthorst M., Van Balken M.R.

Rijnstate, Dept. of Urology, Arnhem, The Netherlands

PT246

Percutaneous tibial nerve stimulation is effective in the treatment of neurogenic overactive bladder in multiple sclerosis patients: A controlled study

By: Pacini P.1, Iacovelli V.1, Petta F.1, D'Ippolito G.1, Ragaglini R.2, Pletto S.1,
<table>
<thead>
<tr>
<th>Carilli M. (^1), Finazzi Agrò E. (^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(^1)Policlinico Tor Vergata Roma, Dept. of Urology, Rome, Italy, (^2)Fondazione Santa Lucia, Dept. of Neuro-Urology, Rome, Italy</td>
</tr>
</tbody>
</table>